{"id":909895,"date":"2025-11-13T16:18:06","date_gmt":"2025-11-13T21:18:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-third-quarter-2025-financial-results-and-provides-business-update\/"},"modified":"2025-11-13T16:18:06","modified_gmt":"2025-11-13T21:18:06","slug":"nucana-reports-third-quarter-2025-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nucana-reports-third-quarter-2025-financial-results-and-provides-business-update\/","title":{"rendered":"NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n
\n Announced Encouraging Data on both NUC-7738 and NUC-3373<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Compliant with All Nasdaq Continued Listing Criteria<\/em>
\n <\/strong>\n <\/p>\n

\n
\n Well Capitalized with Anticipated Cash Runway into 2029 <\/em>
\n <\/strong>\n <\/p>\n

EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (\u201cNuCana\u201d or the \u201cCompany\u201d) announced financial results for the third quarter ended September 30, 2025 and provided an update on its clinical development program with its two lead anti-cancer medicines.<\/p>\n

\u201cWe recently announced promising data for both NUC-7738 and NUC-3373 that continue to support the potential of our ProTides to deliver significantly improved treatment outcomes for patients with cancer,\u201d said Hugh S. Griffith, NuCana\u2019s Chief Executive Officer. \u201cFor NUC-7738, we presented new data at the European Society for Medical Oncology (ESMO) Congress 2025 on NUC-7738 in combination with PD-1 inhibitors in a real-time organoid model system, which revealed that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. These data demonstrate the benefit of combining PD-1 inhibitors with NUC-7738, similar to that seen in patients on the ongoing NuTide:701 study. Based on the exciting initial data from this study, we are currently recruiting an additional 28 patients with PD-1 inhibitor-resistant melanoma and plan to meet with the U.S. Food and Drug Administration to discuss the data from this study to determine the optimal registration strategy to support potential marketing approval.\u201d<\/p>\n

Mr. Griffith continued, \u201cWe also presented new clinical data from the NuTide:303 study, where encouraging signals of durable activity were observed in patients treated with NUC-3373 plus pembrolizumab who had exhausted all standard treatment options, including prior PD-1 inhibitors. Notably, one patient with melanoma remains progression-free at 23 months and continues to exhibit a partial response with an 81% reduction in target lesions. Another patient with urothelial carcinoma of the bladder achieved a 100% reduction in their target lesions and remained on treatment for over 15 months. These clinical findings are further supported by nonclinical data published in September 2025, which corroborate the immunogenic effects of NUC-3373 observed in patients, particularly in combination with a PD-1 inhibitor. We are currently evaluating optimal combinations and indications for further clinical studies of NUC-3373, while continuing to maintain our anticipated cash runway into 2029.\u201d<\/p>\n

Mr. Griffith concluded, \u201cLastly, we have significantly strengthened our balance sheet via the strategic utilization of our at-the-market (\u201cATM\u201d) program in July, extending our cash runway into 2029 and through key value-driving milestones. This initiative, together with the financing in May, raised gross proceeds of $38.4 million, and with multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.\u201d<\/p>\n

\n Anticipated Milestones<\/strong>\n <\/p>\n